David A. Siegel An2 Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 120,900 shares of ANTX stock, worth $154,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,900
Previous 134,700
10.24%
Holding current value
$154,752
Previous $289,000
55.36%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$7.36 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.56 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.99 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.33 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$570,6020.23% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $24.8M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...